Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7577096 | 0.89 | SLC22A12 (0.37) | MCL1CA1CA2PIM1KDM4E | |
| SCHEMBL7571117 | 0.83 | CYP11B1 (0.54) | — | |
| SCHEMBL6988969 | 0.82 | CA1 (0.40) | MCL1CA1CA2KDM4EALDH1A1 | |
| SCHEMBL7577524 | 0.80 | SLC22A12 (0.41) | MCL1CA1CA2KDM4EALDH1A1 | |
| SCHEMBL2353695 | 0.79 | CA1 (0.53) | MCL1CA1CA2PIM1KDM4E | |
| SCHEMBL7577589 | 0.79 | KDM4E (0.43) | MCL1PIM1KDM4EALDH1A1 | |
| SCHEMBL7570617 | 0.79 | AR (0.44) | KDM4EALDH1A1 | |
| SCHEMBL6988176 | 0.78 | PGGT1B (0.42) | KDM4E | |
| SCHEMBL28203557 | 0.77 | CA1 (0.60) | MCL1CA1CA2PIM1KDM4E | |
| SCHEMBL15856480 | 0.77 | MCL1 (0.47) | MCL1CA1CA2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | MCL1 1726/4885CA1 2251/4885CA2 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.